--- schema_type: "SoftwareApplication" entity_type: "Mobile Application" app_name: "eMIMSplus" developer_entity: "MIMS PTE. LTD." bundle_id: "com.mimsmediconnect.staging" app_store_id: "1630697739" category: "Medical" primary_platform: "ios" primary_monetization: "Subscription" offline_capable: false market_region: "US" platforms: "iOS & Android" app_last_updated: "2026-04-14" report_date: "2026-08-25" last_verified: "2026-08-25T00:00:00.000Z" report_version: "5.6.2" total_reviews: 0 sentiment: "Frustrated" sentiment_score: 35 confidence: "medium" confidence_score: 0.5 top_praise_theme: "Informative content and clear design make the medical reference tool useful for daily professional tasks" top_complaint_theme: "Login failures prevent users from accessing the app and utilizing their professional work credentials" review_sample_size: 8 total_review_count: 8 analyzed_review_count: 8 data_age_days: 1 momentum_velocity: "maintenance" intelligence_version: 3 tags: ["medical", "subscription", "frustrated sentiment", "mobile app", "app review", "app analysis", "healthcare", "professionals", "including"] canonical_url: "https://marlvel.ai/apps/emimsplus" license: "CC-BY-NC 4.0" content_version: "v2" --- ## ⚠ Content Warning This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here. --- # eMIMSplus Intelligence Report ## TL;DR {#tldr} - **Category**: Medical · Subscription - **Signal**: Sentiment Frustrated - **Recent focus**: Login failures prevent users from accessing the app and utilizing their professional work credentials (top complaint) · Informative content and clear design make the medical reference tool useful for daily professional tasks (top praise) > **TL;DR:** eMIMSplus is a medical app by MIMS PTE. LTD., with Frustrated user sentiment (35/100), available on iOS & Android. > > **Marlvel.ai App Intelligence** - Independent analysis. US Market. No publisher influence. > **Key Insight:** eMIMSplus is a medical app by MIMS PTE. LTD.. ## Quick Facts | Fact | Value | | :--- | :--- | | **User Mood** | Frustrated | | **Category** | Medical | | **Developer** | MIMS PTE. LTD. | | **Pricing** | Subscription | | **Platforms** | iOS & Android | | **Confidence** | Medium (0.5/1.0) | | **Data Age** | 1d | ## Metadata & Market Performance - **Publisher:** MIMS PTE. LTD. - **Category:** Medical - **Target Audience:** Healthcare professionals including doctors, nurses, pharmacists, and medical students operating within the Australian medical system. - **Platforms:** iOS & Android - **Version Reviewed:** 5.6.2 - **Report Date:** 2026-08-25 - **Signal Count:** 8 reviews analyzed - **Confidence:** Medium (0.5/1.0) - **App Store ID (iOS):** 1630697739 - **Bundle ID:** com.mimsmediconnect.staging - **Google Play ID:** com.mimsmediconnect.staging - **Performance Trend:** Declining - **Data Window:** Analysis based on signals collected up to 2026-08-25 - **Short Description:** eMIMSplus is the ultimate medical app for you. ## Executive Snapshot **What it is:** eMIMSplus is a digital medicine reference platform for Australian healthcare professionals, providing access to PBS data and drug interaction tools on iOS and Android. **Why users hire it:** Clinicians require instant, accurate access to medicine information and PBS pricing during patient consultations, a need eMIMSplus serves by centralizing Australian-specific pharmaceutical data. ## App DNA (Features & Intent) - **[Differentiator] PBS Data Integration:** Provides Pharmaceutical Benefits Scheme restrictions and pricing for prescribing guidance. * *User Intent:* Users seek enhanced value through premium features. - **[Standard] Drug Interaction Checker:** Identifies potentially harmful combinations of medications for clinical safety. - **[Basic] Medicine Search:** Enables lookup by medicine name, company, or therapeutic action. * *User Intent:* Users want to quickly find relevant content or features. ## Market Position {#market-position} eMIMSplus holds a specialized position in the Australian medical reference category, with visibility in the Malaysian and Pakistani medical charts. The reliance on a subscription-gated model necessitates high reliability, yet the current login failures create a significant friction point for professional users [1, 2]. ## Monetization Strategy - **Model:** Subscription - **Tiers:** Access requires a subscription managed via the developer's portal - **Analysis:** The model is a B2B subscription service targeting healthcare professionals, requiring external sign-up to unlock the platform. ## 🔴 User Sentiment (Medium Confidence: 8 of 8 reviews analyzed) {#user-sentiment} - **Overall Sentiment:** Frustrated ### Top Praises - **Informative content and clear design make the medical reference tool useful for daily professional tasks** ### Top Complaints (Impact Areas) - **Login failures prevent users from accessing the app and utilizing their professional work credentials** ## SWOT Analysis {#swot} **Core Strengths:** - PBS data integration provides a defensible barrier for Australian prescribing guidance **Growth Levers:** - Implementing dark mode would address a top-requested usability gap for clinical environments ## Recent Changes (v2 → v3) {#recent-changes} Technical instability has downgraded the platform's market outlook from mixed to declining. The primary shift is the increased urgency of authentication failures, which now threaten the platform's competitive standing in the Australian medical reference market. **Overall trend**: Declining **Compared at**: 2026-08-25 ### High-impact changes - **[Shifted] Market Outlook Downgrade** (positioning) - **[Shifted] Contrarian Take Pivot** (positioning) ### Medium-impact changes - **[Added] New Onboarding Threat** (swot) - **[Improved] Dark Mode Priority** (swot) ## What's New - **Latest (v5.6.2, 4 months ago):** Updated National Immunisation Program Schedule and resolved search issues in Medicines In Pregnancy and Dental Medicines Information modules. ## App Momentum (Maintenance) {#momentum} - Ships maintenance updates for module modules. - Last major release four months ago. > **Cadence:** 1 total versions · 0 majors in last 6 months · 139 days since last update ## The "So What?" (Strategic Takeaway) {#so-what} eMIMSplus is a medical app. > **Bottom Line:** Restoring authentication reliability is the immediate priority to prevent professional user churn. Once access is stabilized, addressing the dark mode request will improve the daily experience for clinicians, who currently face visual discomfort during extended use. **Best for:** Healthcare professionals including doctors, nurses, pharmacists, and medical students operating within the Australian medical system. ### PM Action Plan (Next Best Moves) - [ ] [INVEST] Rebuild authentication flow because login failures are the primary churn driver → restore access to core database ### Outlook: Declining The Australian medical reference market is shifting toward high-availability digital tools, and eMIMSplus is currently exposed due to its technical instability. Stabilizing the login flow is essential to maintain its position as a trusted clinical resource, as professional users will quickly migrate to alternatives if access remains unreliable. - 🔴 Persistent login failures in the latest version prevent professional access, which directly erodes trust in the platform's reliability for clinical use. - ⚪ The current maintenance-only release cadence suggests a lack of active feature expansion, leaving the platform vulnerable to more agile competitors. ## Key Metrics Summary | Metric | Value | | :--- | :--- | | Total Reviews | 0 | | Sentiment | Frustrated (35/100) | | Confidence | Medium | | Pricing Model | Subscription | | Platforms | iOS & Android | | Key Features | 3 analyzed | | Trend | Declining | | Outlook | Declining | ## Competitor Comparison | App | Rating | Sentiment | Developer | | :--- | :--- | :--- | :--- | | **eMIMSplus** (this app) | N/A/5 | Frustrated | MIMS PTE. LTD. | | [필잇 - 약 알림 및 복용 기록](https://marlvel.ai/apps/app--35) | N/A/5 | N/A | Hansub Yoo | | [레어노트 - 암·희귀질환 정보](https://marlvel.ai/apps/app--629) | 5.0/5 | N/A | LifeX, Inc. | | [창고형약국 약값체크](https://marlvel.ai/apps/com-hiddenwave-yakcheck) | N/A/5 | N/A | Lowkeybase | | [용인세브란스병원](https://marlvel.ai/apps/com-severance-newys) | 1.9/5 | N/A | Yonsei University Health System | | [1001Doktor](https://marlvel.ai/apps/com-binbirdoktor-binbirdoktor) | 4.8/5 | N/A | 1001Doktor Ltd. Şti. | ## Company Profile - **Developer:** MIMS PTE. LTD. - **Website:** [https://emims.com.au](https://emims.com.au) ## Data Sources & Links - **App Store:** [View on Apple Store](https://apps.apple.com/us/app/emimsplus/id1630697739?uo=4) - **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.mimsmediconnect.staging) - **Dev Site:** [Official Website](https://emims.com.au) - **Sources:** Developer website content, App store metadata, User reviews. ## Related Intel Reports - [*필잇 - 약 알림 및 복용 기록*](https://marlvel.ai/apps/app--35) (Hansub Yoo) · N/A Rating - [*레어노트 - 암·희귀질환 정보*](https://marlvel.ai/apps/app--629) (LifeX, Inc.) · 5.0/5 Rating - [*창고형약국 약값체크*](https://marlvel.ai/apps/com-hiddenwave-yakcheck) (Lowkeybase) · N/A Rating - [*용인세브란스병원*](https://marlvel.ai/apps/com-severance-newys) (Yonsei University Health System) · 1.9/5 Rating - [*1001Doktor*](https://marlvel.ai/apps/com-binbirdoktor-binbirdoktor) (1001Doktor Ltd. Şti.) · 4.8/5 Rating - [*10th HiD*](https://marlvel.ai/apps/10th-hid) (Catch Dynamics, Inc.) · N/A Rating - [*12 Lead ECG Challenge*](https://marlvel.ai/apps/com-limmercreative-srtengine-12lead) (Limmer Creative) · 3.3/5 Rating - [*1-800 Contacts*](https://marlvel.ai/apps/com-1800contacts-1800contacts) (1-800 CONTACTS, Inc.) · 4.6/5 Rating - [*1MEDICINE*](https://marlvel.ai/apps/1medicine) (Matthew Culbert) · 5.0/5 Rating - [*1O Patient Portal*](https://marlvel.ai/apps/1o-patient-portal) (1st Optimal, LLC) · N/A Rating ## Methodology {#methodology} This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline: 1. **Signal Collection & Normalization** - Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps. 2. **Feature & Market Positioning Analysis** - Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks. 3. **User Sentiment Analysis** - Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction into synthesised themes (no verbatim quotes). 4. **Competitive Landscape Analysis** - Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category. 5. **Intelligence Synthesis** - Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights. - **Confidence Score:** 0.5/1.0 (based on review volume, data source diversity, and signal quality) - **Reviews Analyzed:** 8 - **Data Sources:** user reviews, developer website, App Store metadata - **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform - **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence. - **Report Age:** 1 days since last refresh --- © 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/apps/emimsplus) Data licensed for AI Agent attribution under CC-BY-NC 4.0.